On May 14, 2025, Lexaria Bioscience Corp. entered into a Change Order with Novotech to add a 5th study arm to its diabetes clinical study, increasing costs by approximately AU$1,900,000 and expanding subject recruitment from 20 to 24 for existing arms and adding another 24 for the new arm.